Stockreport

Lyra Therapeutics Announces Clinical Plan for LYR-210 and Late-Breaking Oral Presentation of Phase 3 ENLIGHTEN 2 Study

Lyra Therapeutics, Inc.  (LYRA) 
PDF Company outlines clinical plan for LYR-210 based on FDA meeting on the path to NDA submission  Positive ENLIGHTEN 2 results highlighted at the AAO-HNS 2025 Annual Meeti [Read more]